Abstract
microRNAs (miRNAs), small non-coding RNA molecules that act as negative regulators of gene expression, are involved in a wide range of biological functions and control several cellular processes. This review illustrates miRNA regulation and function in tissue response to acute ischemia, focusing on miRNA role in acute myocardial infarction and describing a subset of miRNAs de-regulated upon cardiac ischemia. These miRNAs may represent “master ischemic” miRNAs, playing a pathogenetic role in one of the different components of tissue response to ischemia. Moreover, circulating miRNAs correlated to myocardial infarction and examples of miRNA involvement in ischemic diseases different from cardiac ischemia are also discussed. The identification of specific miRNAs as key regulators of cell biology has opened new clinical avenues, and may allow new diagnostic and/or prognostic tools development, as much as innovative therapeutic strategies. Two paradigmatic reports, in which miRNAs have been targeted to improve cardiac function in pre-clinical models of myocardial infarction, are described in detail and confirmed the efficacy of these strategies.
Keywords: microRNAs, acute myocardial ischemia, ischemic diseases, miRNA-based therapy.
Current Vascular Pharmacology
Title:microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Volume: 13 Issue: 3
Author(s): Pasquale Fasanaro, Yuri D'Alessandra, Alessandra Magenta, Giulio Pompilio and Maurizio C. Capogrossi*
Affiliation:
- Laboratorio di Patologia Vascolare, Istituto Dermopatico dell’Immacolata-IRCCS, Roma,Italy
Keywords: microRNAs, acute myocardial ischemia, ischemic diseases, miRNA-based therapy.
Abstract: microRNAs (miRNAs), small non-coding RNA molecules that act as negative regulators of gene expression, are involved in a wide range of biological functions and control several cellular processes. This review illustrates miRNA regulation and function in tissue response to acute ischemia, focusing on miRNA role in acute myocardial infarction and describing a subset of miRNAs de-regulated upon cardiac ischemia. These miRNAs may represent “master ischemic” miRNAs, playing a pathogenetic role in one of the different components of tissue response to ischemia. Moreover, circulating miRNAs correlated to myocardial infarction and examples of miRNA involvement in ischemic diseases different from cardiac ischemia are also discussed. The identification of specific miRNAs as key regulators of cell biology has opened new clinical avenues, and may allow new diagnostic and/or prognostic tools development, as much as innovative therapeutic strategies. Two paradigmatic reports, in which miRNAs have been targeted to improve cardiac function in pre-clinical models of myocardial infarction, are described in detail and confirmed the efficacy of these strategies.
Export Options
About this article
Cite this article as:
Fasanaro Pasquale, D'Alessandra Yuri , Magenta Alessandra, Pompilio Giulio and Capogrossi C. Maurizio*, microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/15701611113119990011
DOI https://dx.doi.org/10.2174/15701611113119990011 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins and Metabolism of High Density Lipoprotein
Cardiovascular & Hematological Agents in Medicinal Chemistry The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age- Related Macular Degeneration
Current Drug Therapy Chemistry and Biological Activities of Buxus Alkaloids
Current Bioactive Compounds Integrating Coronary Calcium into Risk Prediction: Current Approaches and Future Directions
Current Cardiology Reviews Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design MicroRNA Therapeutics for Cardiac Regeneration
Mini-Reviews in Medicinal Chemistry The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research Insights in microRNAs Biology
Current Topics in Medicinal Chemistry Assessing Myocardial Metabolism with Hybrid PET Imaging: Instrumentation, Concepts, and Workflows
Current Pharmaceutical Design Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry